David has over 35 years’ investment markets experience, serving as Chairman in executive and non-executive capacities for a number of public and private companies.  He has overseen the development of these companies, raising in excess of £1 billion of capital to support both organic and acquisitive growth initiatives.  David was formally Chairman of Entertainment One Ltd. (LSE: ETO) and Zetar plc, and is currently a non-executive director of Breedon Group plc (AIM: BREE) and Chairman of Aurum Mining plc (AIM: AUR).

He is Chairman of the Nomination Committee and a member of the Remuneration and Audit Committees.

Christian read Politics, Philosophy and Economics at Lincoln College, Oxford.  His career started at the Boston Consulting Group where he worked both in Europe and the US. He then moved to the UK Holding Company a subsidiary of the German/Dutch Conglomerate, Hoogovens/Hoechst as a director of two of their subsidiaries in the UK, winning the Queen’s award for Exports in one of those subsidiaries. He then became Vice President of Fox Pitt Kelton, where he worked on the mergers and acquisitions of US Regional Banks.  Subsequently, Christian embarked on career in venture capital, initially in conjunction with Ensign Trust PLC, owned by the Merchant Navy Pension Fund.  Christian founded Oxford BioDynamics in 2007 with Dr. Alexandre Akoulitchev and Dr. Aroul Ramadass.  Christian was the Chairman of both Chronos Therapeutics Limited and Sibelius Limited until August 2016, at which point he stepped down from both roles.   He is now a Non-Executive Director of both Chronos Therapeutics Limited and Sibelius Limited. Christian sits on the Nomination Committee.

Alexandre Akoulitchev

Alexandre read mathematics, physics, chemistry, biochemistry and biophysics at Moscow Institute of Physics and Technology.  In 1989 he was selected by the George Soros Foundation for the Oxford Scholarship, associated with St. Antony’s College, along with 20 top Soviet graduate students from the USSR. He obtained his PhD in cell biology from University College, London (with the research based at the Imperial Cancer Research Fund). He spent six years at the Robert Wood Johnson Medical School-UMDNJ, NJ, as a research assistant funded by the Howard Hughes Medical Institute. Upon his return to England, he established his research laboratory at the Sir William Dunn School of Pathology, University of Oxford.  He was a University Academic Fellow (Research Council UK) and a Senior Fellow of Exeter College, sponsored by Cancer Research UK, the Wellcome Trust, The Medical Research Council and Monsanto Foundation.  Alexandre is also a Fellow of the Royal Society of Medicine.  He is currently a Non-Executive Director of Sibelius Limited.

Katie qualified as a Chartered Accountant in 2002 with the Institute of Chartered Accountants Australia and has a degree in Commerce from the University of Melbourne.  Katie started her career as an auditor at Ernst & Young, working on external audits within the financial services sector, and then moved into banking, focusing on the financial reporting of complex structured products under IFRS and US GAAP.  In 2008, Katie joined Marwyn Capital LLP as an Investment Manager, where she was responsible for a number of the fund’s investments, and the provision of corporate finance advice to listed portfolio companies.  In 2012, Katie co-founded Tessera Investment Management Limited, a specialist provider of in-house transaction management support to both public and private companies undertaking M&A and capital raising activities, where she remains a Director.

Alison read Biochemistry at New College, Oxford. Her career stared as a product manager of R&D Systems Europe Limited in 1992, after which she moved on to become General Manager of Quantum Appligene and a consultant to Actigen Limited.  In 2000, Alison became the Sales Director of eLabs Europe and in 2001 became the CEO of Molecular Sensing plc.  She transitioned Molecular Sensing plc from the R&D phase through project development to launch of their first commercial product and was instrumental in technology transfer and eventual licence of the technology to Roche, before sale of the company to Osmetech plc.  In 2005, Alison was recruited as the CEO of Femeda Ltd.  Through her company, Lobes Ltd, she acts as a Board advisor and Non-Executive Director for a number of companies, ranging from start-ups to more established businesses. She specialises in commercialisation strategies and fund-raising.  Alison formerly represented Oxford University on the Board of Directors for the Company. Alison serves as Chairman of the Remuneration Committee and sits on the Nomination and Audit Committees.

Stephen is the founder and Chief Executive Officer of Vulpes Investment Management, and co-founder and former managing partner of Artradis Fund Management, one of the largest hedge fund groups in Asia.  Stephen has been involved in equity capital markets for nearly 30 years, leading trading teams across a number of institutions including Salomon Brothers and Lehman Brothers, and has considerable experience investing in and supporting life science businesses through the Vulpes Life Sciences Fund.  Stephen holds an MA from the University of Oxford.